Obstetric cholestasis (OC) is a liver disorder that occurs in the late second and early third trimester of pregnancy characterized by pruritus with increased serum bile acids and other liver function tests. The pathophysiology of OC is still not completely understood. The symptoms and biochemical abnormality rapidly resolve after delivery. OC is associated with an increased risk of adverse obstetrical outcomes. The aetiology of obstetric cholestasis of pregnancy is poorly understood and is thought to be complicated and multifactorial. OC typically occurs in the late second trimester when the oestrogen levels are the highest in pregnancy. The most common complaint is generalized intense pruritus, which usually starts after the 30th week of pregnancy. Pruritus can be more common in the palms and soles and is typically worse at night. Other symptoms of cholestasis, such as nausea, anorexia, fatigue, right upper quadrant pain, dark urine, and pale stool, can be present. Clinical jaundice is rare but may present in 14% to 25% of patients after 1 to 4 weeks of the onset of pruritus. Some patients also complain of insomnia as a result of pruritus. Generally, physical examination is unremarkable except for scratch marks on the skin from pruritus. Pruritus is a cardinal symptom of intra-hepatic cholestasis of pregnancy (ICP) and may precede biochemical abnormalities. The diagnosis of intrahepatic cholestasis of pregnancy is via the presence of clinical symptoms pruritus in the third trimester with elevated maternal total serum bile acids and excluding other diagnoses, which can cause similar symptoms and lab abnormalities. Fasting blood samples should be used to check for the total bile salt acid level as it can become elevated in the postprandial state.
Once the diagnosis of OC of pregnancy is confirmed, immediate treatment is necessary, and the primary goal of therapy is to decrease the risk of perinatal morbidity and mortality and to alleviate maternal symptoms. Maternal pruritus can be alleviated with use of moisturisers and oral antihistamines. Ursodeoxycholic acid (UDCA) is the drug of choice for the treatment of ICP.
Many authors have advocated elective early delivery of women with intrahepatic cholestasis of pregnancy to reduce the risk of sudden foetal death. The Royal College of Obstetricians and Gynaecologists recommends induction of labour after 37+0 weeks of gestation. Obstetric cholestasis of pregnancy is not an indication for Caesarean delivery. Postpartum pruritus typically disappears in the first 2 to 3 days following delivery, and serum bile acid concentrations will normalize eventually. ICP is not a contraindication to breastfeeding, and mothers with a history of ICP in pregnancy can breastfeed their infants. Postpartum monitoring and follow up of bile acids and liver function tests should be done in 4-6 weeks to ensure resolution. Women with the persistent abnormality of liver function test after 6 to 8 weeks require investigation for other aetiologies.
Clinical Updates in Women's Health Care Summary: Liver Disease: Reproductive Considerations. Obstet Gynecol. 2017 Jan;129(1):236. [PubMed].
Williamson C, Geenes V. Intrahepatic cholestasis of pregnancy. Obstet Gynecol. 2014 Jul; 124 (1):120-33. [PubMed].
Kenyon AP, Tribe RM, Nelson-Piercy C, Girling JC, Williamson C, Seed PT, et al. Pruritus in pregnancy: a study of anatomical distribution and prevalence in relation to the development of obstetric cholestasis. Obstet Med 2010; 3:25–9.
Abedin P, Weaver JB, Egginton E. Intrahepatic cholestasis of pregnancy: prevalence and ethnic distribution. Ethn Health 1999; 4:35–7.
Reyes H, Gonzalez MC, Ribalta J, Aburto H, Matus C, Schramm G, et al. Prevalence of intrahepatic cholestasis of pregnancy in Chile. Ann Intern Med 1978; 88:487–93.
Turunen K, Helander K, Mattila KJ, Sumanen M. Intrahepatic cholestasis of pregnancy is common among patients' first-degree relatives. Acta Obstet Gynecol Scand. 2013 Sep; 92(9):1108-10. [PubMed].
Pataia V, Dixon PH, Williamson C. Pregnancy and bile acid disorders. Am J Physiol Gastrointest Liver Physiol. 2017 Jul 01; 313(1):G1-G6. [PubMed].
Kenyon AP, Girling JC. Obstetric Cholestasis. In: Studd J, editor. Progress in Obstetrics and Gynaecology: Volume 16. Edinburgh: Churchill Livingstone; 2004.p. 37–56.
Ambros-Rudolph CM, Müllegger RR, Vaughan-Jones SA, Kerl H, Black MM .The specific dermatoses of pregnancy revisited and reclassified: results of a retrospective two-centre study on 505 pregnant patients. J Am Acad Dermatol 2006; 54:395–404.
Girling JC, Dow E, Smith JH. Liver function tests in preeclampsia: importance of comparison with a reference range derived for normal pregnancy. Br J Obstet Gynaecol 1997; 104:246–50.
Kenyon AP, Piercy CN, Girling J, Williamson C, Tribe RM, Shennan AH. Obstetric cholestasis, outcome with active management: a series of 70 cases. BJOG 2002; 109: 282–8.
Bacq Y, Sapey T, Bréchot MC, Pierre F, Fignon A, Dubois F. Intrahepatic cholestasis of pregnancy: a French prospective study. Hepatology 1997; 26:358–64.
Reid R, Ivey KJ, Rencoret RH, Storey B. Fetal complications of obstetric cholestasis. Br Med J 1976;1:870–2.
Shaw D, Frohlich J,Wittman BAK, Willms M.A prospective study of 18 patients with cholestasis of pregnancy. Am J Obstet Gynecol 1982; 142:621–5.
Berg B, Helm G, Pertersohn L, Tryding N. Cholestasis of pregnancy. Clinical and laboratory studies.Acta Obstet Gynecol Scand 1986; 65: 107–13.
Fisk NM, Storey GN. Fetal outcome in obstetric cholestasis. Br J Obstet Gynaecol 1988; 95: 1137–43.
Rioseco AJ, Ivankovic MB, Manzur A, Hamed F, Kato SR, Parer JT, et al. Intrahepatic cholestasis of pregnancy: a retrospective case–control study of perinatal outcome. Am J Obstet Gynecol 1994; 170:890–5.
Roncaglia N, Arreghini A, Locatelli A, Bellini P, Andreotti C, Ghidini A. Obstetric cholestasis: outcome with active management. Eur J Obstet Gynecol Reprod Biol 2002; 100:167–70.
Kenyon, AP, Piercy CN, Girling J, Williamson C, Tribe RM, Shennan AH. Pruritus may precede abnormal liver function tests in pregnant women with obstetric cholestasis: a longitudinal analysis.BJOG 2001; 108: 1190–2.
Alsulyman OM, Ouzounian JG, Ames-Castro M, Goodwin TM. Intrahepatic cholestasis of pregnancy: perinatal outcome associated with expectant management. Am J Obstet Gynecol 1996; 175: 957–60.
Glantz A, Marschall HU, Mattsson LA. Intrahepatic cholestasis of pregnancy: relationships between bile acid levels and fetal complication rates.Hepatology 2004; 40:467–74.
Lee RH, Kwok KM, Ingles S, Wilson ML, Mullin P, Incerpi M, et al. Pregnancy outcomes during an era of aggressive management for intrahepatic cholestasis of pregnancy. Am J Perinatol 2008; 25: 341–5.
Kaaja RJ, Kontula KK, Räihä A, Laatikainen T. Treatment of cholestasis of pregnancy with peroral activated charcoal.A preliminary study. Scand J Gastroenterol 1994; 2 9:178–81.
Riikonen S, Savonius H, Gylling H, Nikkilä K, Tuomi AM, Miettinen TA. Oral guar gum, a gel-forming dietary fibre relieves pruritus in intrahepatic cholestasis of pregnancy. Acta Obstet Gynecol Scand 2000; 79:260–4.
Jenkins JK, Booth by LA. Treatment of itching associated with intrahepatic cholestasis of pregnancy. Ann Pharmacother 2002; 36:1462–5.
Serrano MA, Brites D, Larena MG, Monte MJ, Bravo MP, Oliviera N, et al. Beneficial effect of ursodeoxycholic acid on alterations induced by cholestasis of pregnancy in bile acid transport across the human placenta. J Hepatol 1998; 28:829–39.
Gorelik J, Shevchuk AI,Diakonov I, de Swiet M, Lab M, KorchevY, et al.Dexamethasone and ursodeoxycholic acid protect against the arrhythmogenic effect of taurocholate in an in vitro study of rat cardiomyocytes.BJOG 2003;110:467–74.
Hirvioja M,Tuimala R,Vuori J. The treatment of intrahepatic cholestasis of pregnancy by dexamethasone.Br J Obstet Gynaecol 1992;99:109–11.
Kretowicz E, McIntyre D. Intrahepatic cholestasis of pregnancy, worsening after dexamethasone.Aust N Z J Obstet Gynaecol 1994; 34:211–3.
Diac M,Kenyon A,Nelson-Piercy C,Girling J,Cheng F,Tribe RM, et al. Dexamethasone in the treatment of obstetric cholestasis: a case series. J Obstet Gynaecol 2006; 26:110–4.
Vidaeff AC, Mastrobattista JM. Controversies in the use of antenatal steroids for fetal maturation. Semin Perinatol 2001; 25:385–96.
Reyes H,Radrigan ME,Gonzalez MC, Latorre R,Ribalta J, Segovia N, et al. Steatorrhea in patients with intrahepatic cholestasis of pregnancy.Gastroenterology 1987;93:584–90.
British Medical Association, Pharmaceutical Society of Great Britain.Vitamin K.British National Formulary. London: British Medical Association, Pharmaceutical Society of Great Britain, 2010.
Saleh MM, Abdo KR.Consensus on the management of obstetric cholestasis: national UK survey.BJOG 2007; 114:99–103.
Shaw D, Frohlich J,Wittmann BAK,Willms M.A prospective study of 18 patients with cholestasis of pregnancy. Am J Obstet Gynecol 1982; 142:621–5.